Microneedle patch testing to predict allergy treatment response
Part of Ear, nose & throat, Immune system & allergy, Lungs & breathing clinical trials.
This study uses a small microneedle patch to collect skin-related samples to help predict how well allergy immunotherapy may work. It includes people with house dust mite allergy and also a healthy control group, so researchers can compare biomarker results.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 19 to 60 years old
- Have allergic rhinitis caused by house dust mites, confirmed by allergy blood/skin testing (MAST Class 3+ or ImmunoCAP 3.5 kUA/L+)
- Have moderate to severe persistent nasal allergy symptoms (per ARIA severity criteria)
- For the house dust mite group, agree to use the microneedle patch and sign written informed consent
- For the healthy control group, be free of allergic or skin diseases and agree to provide human samples
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests whether dust-mite allergy treatment (likely allergy shots) can reduce allergy symptoms and improve safety. It focuses on people whose nose/eye allergy is triggered by house dust mites and who may also have controlled asthma.
This study checks how well a newer, detailed allergy test (using specific allergen components) can guide whether you should get allergy immunotherapy (allergy shots) for things like dust mites or grass pollen. It may help patients get the right treatment plan by improving how doctors confirm what allergens are driving symptoms.
This phase 3 trial tests a specific allergy treatment (an “immunotherapy” shot) for people whose symptoms are triggered by grass and cypress tree pollen. It aims to see if the treatment is safer and more effective at reducing allergy symptoms over time, especially for nose/eye symptoms and some people with asthma.
This trial tests a spray placed under the tongue to treat allergic rhinitis caused by dust mites, pet dander, or mold. It looks at how the spray affects the bacteria in your nose and body.
This trial tests an under-the-tongue tablet for people with dust mite allergies causing moderate to severe nasal symptoms or mild-to-moderate asthma. The goal is to see if it improves symptoms and can replace or reduce the need for allergy medicines.
This trial tests if allergy shots (allergen-specific immunotherapy) can reduce symptoms of moderate to severe dust mite allergy. You will be in a room that exposes you to dust mites to see how well the treatment works, compared to a placebo.
Hear when a new Rhinitis, Allergic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.